T he prognostic importance of white coat (WC) hypertension (WCH), that is, a condition characterized by an increase of office but a normal ambulatory or home blood pressure (BP) 1 is since a long time matter of considerable debate. [2] [3] [4] [5] This is because although in several studies and meta-analyses WCH has been reported to have a cardiovascular risk similar or not significantly greater than that of normotensive individuals, [6] [7] [8] [9] [10] [11] [12] in other studies the risk of this condition in untreated or treated patients has been found to be less than that of true hypertensive but greater than that of normotensive individuals. [13] [14] [15] [16] [17] [18] Individual studies and meta-analyses have also reported that compared with normotensive controls subjects with WCH exhibit (1) a higher prevalence of overweight or obesity, dyslipidemias, diabetes mellitus, or an impaired fasting plasma glucose state than normotensive controls, 1 (2) a greater prevalence of asymptomatic organ damage [19] [20] [21] with documented prognostic significance, [22] [23] [24] [25] and (3) an increased risk of developing true hypertension or diabetes mellitus. 26, 27 Stratifying cardiovascular risk within the WCH categories is of obvious clinical importance because higher risk levels may justify the decision to adopt a closer follow-up as well as to start antihypertensive drug treatment. This can be obtained by thorough hematochemical and instrumental examinations to identify subjects with associated metabolic risk factors and subclinical organ functional or structural alterations. It can further be obtained by measuring both ambulatory and home BP because WC hypertensives in whom both out-of-office BP values are normal have been shown to have a lower cardiovascular risk than those in whom one out-of-office BP is normal, whereas the other is elevated.
T he prognostic importance of white coat (WC) hypertension (WCH) , that is, a condition characterized by an increase of office but a normal ambulatory or home blood pressure (BP) 1 is since a long time matter of considerable debate. [2] [3] [4] [5] This is because although in several studies and meta-analyses WCH has been reported to have a cardiovascular risk similar or not significantly greater than that of normotensive individuals, [6] [7] [8] [9] [10] [11] [12] in other studies the risk of this condition in untreated or treated patients has been found to be less than that of true hypertensive but greater than that of normotensive individuals. [13] [14] [15] [16] [17] [18] Individual studies and meta-analyses have also reported that compared with normotensive controls subjects with WCH exhibit (1) a higher prevalence of overweight or obesity, dyslipidemias, diabetes mellitus, or an impaired fasting plasma glucose state than normotensive controls, 1 (2) a greater prevalence of asymptomatic organ damage [19] [20] [21] with documented prognostic significance, [22] [23] [24] [25] and (3) an increased risk of developing true hypertension or diabetes mellitus. 26, 27 Stratifying cardiovascular risk within the WCH categories is of obvious clinical importance because higher risk levels may justify the decision to adopt a closer follow-up as well as to start antihypertensive drug treatment. This can be obtained by thorough hematochemical and instrumental examinations to identify subjects with associated metabolic risk factors and subclinical organ functional or structural alterations. It can further be obtained by measuring both ambulatory and home BP because WC hypertensives in whom both out-of-office BP values are normal have been shown to have a lower cardiovascular risk than those in whom one out-of-office BP is normal, whereas the other is elevated. 16 In the present study, we have investigated another possibility to distinguish, within the WCH category, individuals at different cardiovascular risk, that is, whether cardiovascular risk differs between those in whom WCH is or not persistent at subsequent versus initial office BP measurements. We have used the data obtained in the Pressioni Arteriose Monitorate E Loro Alterazioni (PAMELA) population in which WCH was identified by office versus ambulatory BP values and the incidence of cardiovascular fatal events was followed up for >16 years. Data analysis was limited to untreated WCH hypertensives (versus untreated normotensive controls) to avoid the confounding effect of BP-lowering interventions.
the residents of Monza (a town located at the North-East outskirts of Milan) to be representative of its population for sex, age, decades (25-74 years), and socioeconomic characteristics, according to the criteria used in the World Health Organization Multinational Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA) study performed in the same geographical area. The overall participation rate was 64% (n=2051), consistently for age and sex strata. The demographic characteristics of nonparticipants were similar to those of participants. This was the case also for major cardiovascular risk factors based on information collected via phone interviews.
Between 1991 and 1993 participants were invited to come to the outpatient sector of the S. Gerardo Hospital of Monza in the morning of a working day, where office BP was measured 3× by a mercury sphygmomanometer after subjects had sat for 10 minutes. Ambulatory BP monitoring (Spacelab 90207, Spacelab) was started after completion of the office BP measurements, with the readings set at 20-minute intervals. Subjects were discharged after the beginning of the monitoring period with the instructions to (1) attend at their usual activities and (2) come back to the hospital the next morning for the device's removal. Removal of the ambulatory BP device was followed by 3 other office BP measurements, again after 10 minutes of rest with the patient in the sitting position. Other collected variables were height and weight (to calculate body mass index), serum total cholesterol and glucose (standard radioenzymatic method), information on history of cardiovascular events, diabetes mellitus, antihypertensive drug treatment, smoking, and other lifestyle habits. In each subject measurements included an echocardiogram, which allowed to calculate left ventricular mass index based on normalization for body surface area.
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Follow-Up and Data Analysis
From the time of initial visit to September 2008 (average follow-up of 16 years) a copy of the death certificate was obtained from the subjects who died. The causes of death reported in the certificate were coded according to the International Classification of Diseases, Tenth Revision. 30 The office BP values obtained before and those obtained after ambulatory BP monitoring were separately averaged. The ambulatory BP values were edited from artifacts according to preselected criteria 31 and averaged from the 24-hour monitoring period. Valid 24-hour readings were close to the expected number of readings (n=72), their percentage being on average similar for the day and night time (95.5% and 95.8%, respectively). WCH was diagnosed by an elevation of average office BP, that is, ≥140 mm Hg systolic or ≥90 mm Hg diastolic BP and a normal 24-hour mean BP value. Twenty-four-hour BP normality was defined based on (1) 
Results
Baseline Characteristics
As shown in Table 1 , several baseline variables differed between normotensives and unstable or stable WCH subjects. Compared with normotensive subjects, male sex and 24-hour BP showed a similar increase in the 2 WCH groups, whereas age, first and second visit office BP, mean of the 6 office BP values, metabolic variables, history of cardiovascular disease and left ventricular mass index all exhibited a greater value in stable versus unstable WCH subjects. Compared with the data obtained using the PAMELAderived cutoff normality values for ambulatory BP, similar differences were observed with use of the international guidelines ambulatory normality values. Median followup was 214, 215, 213, and 209 months in normotensive, unstable WCH, and stable WCH patients, respectively (214 months in the whole group).
Cardiovascular and All-Cause Mortality Incidence and Risk
During the 16-year follow-up there were 22 cardiovascular and 112 all-cause deaths in the 3 groups subdivided according to the PAMELA cutoff values for ambulatory BP normality. The corresponding numbers for the 3 groups subdivided according to the guidelines cutoff values were 26 and 132. Figure 1 shows that, with both the PAMELA and the guidelines ambulatory BP cutoff values, the incidence of cardiovascular and all-cause deaths increased progressively from normotension to unstable and stable WCH. As shown in Figure 2 , when data were analyzed according to the PAMELA-derived ambulatory BP normality cutoff values, the risk of cardiovascular and all-cause mortality for 1 SD increase did not usually differ significantly between normotensive and unstable WCH subjects. This was the case regardless whether WCH was present at the first or the second visit (hazard ratio for cardiovascular mortality, respectively, 3.7; 95% confidence interval [CI], 0.4-31.1; P=0.2 and 1.1; 95% CI, 0.1-18.9; P=0.9; hazard ratio for all-cause mortality, respectively, 0.7; 95% CI, 0.3-1.6; P=0.4 and 0.6; 95% CI, 0.2-1.3; P=0.2). On the contrary, in stable WCH subjects the mortality risk was always significantly increased, this being the case also when data were adjusted for baseline confounders and adjustment was extended to 24-hour mean BP values. After data were additionally adjusted for office BP (mean of 6 values, see Table 1 ), the hazard ratio of all-cause mortality in stable WCH became not significantly different (1.6; 95% CI, 0.7-3.7; P=0.3) from that of normotensive subjects, whereas that of cardiovascular mortality remained significantly higher (38.1; 95% CI, 3.8-377.4; P=0.002) in stable WCH as compared with normotensive subjects. Similar results were obtained when data were analyzed according to the guidelines-defined ambulatory BP normality cutoff values (Figure 3 ). Tables 2 and 3 show the results of the multivariable analyses, which considered available baseline data as the independent variables and cardiovascular or all-cause mortality as the dependent one. Office systolic BP was the most important variable independently predicting cardiovascular mortality followed by age, body mass index, and male sex. Office systolic BP was an independent predictor also of all-cause mortality after age and history of cardiovascular disease and before left ventricular mass index. 
Multivariable Analyses
Discussion
In the subjects of the PAMELA population in whom a normal ambulatory BP was accompanied by an inconsistent elevation of office BP, that is, the elevation was seen at 1 but not at the 2 available visits, (1) the incidence of cardiovascular and all-cause deaths was not substantially greater than and (2) the unadjusted or adjusted risk of cardiovascular and all-cause mortality was not significantly different from that of control subjects, that is, subjects with normal office and ambulatory BP values throughout. In contrast, in subjects with a normal ambulatory BP in whom an elevation of office BP was found at both visits, the incidence of fatal events was greater than in the control group, the risk of both cardiovascular and allcause mortality being significantly increased also when data were adjusted for potential confounders such as demographic variables, history of cardiovascular disease, metabolic risk factors, serum creatinine, and cardiac organ damage. This allows to conclude that a stable WCH condition, as determined by a 2 visit detection of an office BP elevation, is associated with a clearcut increase of cardiovascular risk, whereas this does not occur when detection of WCH at first visit is not confirmed at a second visit.
In the stable and unstable WCH individuals of our population 24-hour systolic and diastolic BP did not differ, the BP difference being limited to greater office values in the former than in the latter group. This rules out the possibility that ambulatory BP was responsible for the different outcome results. It rather scores in favor of a prognostic role of office BP, a conclusion supported by the observation that (1) the risk of cardiovascular and all-cause mortality remained greater in stable than in unstable WCH subjects also when adjustment included ambulatory BP; (2) at multivariable analysis office BP was found to be among the independent predictors of both events, whereas this was not the case for ambulatory BP; and (3) the difference in all-cause mortality risk between normotensive and stable WCH subjects became not significant after adjustment for office BP values, although the increased risk of cardiovascular mortality persisted. Without denying the well-established importance of ambulatory BP in the determination of cardiovascular risk, 18, [33] [34] [35] this warns against interpretation of available data as indicative that office BP plays little or no independent prognostic role. It appears from the present study that in WCH office BP predicts, together with other factors, long-term outcome and that its elevation contributes to the increased risk of cardiovascular events 15 as well as to the higher prevalence of subclinical cardiac and vascular damage reported for this condition in several studies. 13, [19] [20] [21] 26, 27, 36, 37 The following additional points deserve mention. One, compared with individuals in whom WCH was unstable, stable WCH was characterized by an older age, a greater body mass index, an increased left ventricular mass, and higher serum cholesterol and glucose values. Thus, factors other than the persistently elevated office BP may be abnormal in stable WCH, its increased cardiovascular risk being thus generated not only by an office BP elevation but also by risk factors other than BP. Two, the differences in baseline and mortality risks between stable WCH, unstable WCH, and control subjects were similar when 24-hour BP normality was defined by the values indicated by international guidelines (<130/80 mm Hg) 1 and when the lower normality values derived from the PAMELA population data (<125/79 mm Hg) were used. 28 That the results remained unaltered also when a particularly stringent definition of WCH (such as that derived from the PAMELA data) was used ensures against the possibility that the WCH groups included individuals with an ambulatory BP elevation and that this was responsible for the increased outcome risk that was observed in stable WCH. Three, our observations do not provide support to the recommendations of the UK guidelines of the National Institute for Health and Care Excellence to exclude from frequent follow-up visits and treatment WCH individuals based on a single set of office and ambulatory BP data.
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According to our results, this approach may miss the existence of a considerable increase of cardiovascular risk in some individuals.
Finally, our study has strengths but also limitations. One strength is that follow-up was extended to 16 years, which allows the results to reflect long-term cardiovascular risk. Another is that, as reported in previous studies, 28, 39 in the PAMELA population both ambulatory and office BP values were of a high technical quality. Namely, (1) multiple office BP values were obtained in a standardized fashion by trained personnel and (2) there were only few artifacts during ambulatory BP monitoring, the 24-hour mean values being thus derived from a large number of valid readings homogeneously distributed during the recording period. The limitations are that in the PAMELA study only 2 sets of office BP values were available together with only 1 ambulatory BP monitoring. There was thus no chance to see whether prognosis of WCH individuals is affected also by stability of (1) ambulatory BP normality or (2) office BP values over a greater and more widespread number of visits. However, that a clear prognostic differentiation of WCH individuals could be achieved by 2 close visits only makes the approach easily adoptable to grade WCH patients' risk in clinical practice. Furthermore, our outcomes were limited to fatal events, the cardiovascular ones being in some groups only few, with a reduced study statistical power. However, the cardiovascular results were closely reflected by those on all-cause mortality, whose number was much greater. Finally, although the analysis only involved individuals with no antihypertensive treatment at baseline, one cannot exclude that antihypertensive drugs were administered during follow-up and that their favorable effect on the incidence of cardiovascular events 40 had an impact on the results. However, because of the more persistent office BP elevation and the adverse cardiovascular risk profile, antihypertensive drug administration was more likely to have started in stable than in unstable WCH. This possibility is supported by the data obtained in subjects who were restudied 10 years later. 26 During this time interval antihypertensive drug treatment was reported to have started in 8.5% of 659 initially untreated normotensive subjects, 18.4% of 136 initially untreated unstable WCH subjects, and 42.3% of 78 initially untreated stable WCH individuals. It should additionally be mentioned that treatment may have caused a reduction of cardiovascular risk that attenuated rather than enhancing the difference between the 2 conditions.
In conclusion, our study provides 2 main findings. The former is that in WCH the long-term incidence of fatal events is much greater when office BP is found to be elevated at 2 consecutive visits. This implies that, to properly quantify their cardiovascular as well as overall risk (and thus take a more informed decision about treatment), office BP values must be obtained at multiple visits. The latter finding is that in the stable WCH condition the adverse risk is accounted for by the persistent office BP elevation. This means that in WCH office, and not just out-of-office, BP is an important independent component of the overall risk of this condition.
Perspectives
In the PAMELA population, the long-term risk of cardiovascular and all-cause mortality exhibited by WCH individuals in whom office BP values remained elevated at subsequent office BP measurements (stable WHC) was higher than that of WCH individuals in whom only 1 office BP was elevated (unstable WCH) whose risk did not differ significantly from that of normotensive controls. Thus, among subjects with WCH, the risk of mortality can be stratified by collecting office BP values at different visits. Repetition of office BP measurement should thus be regarded as a desirable procedure when dealing with subjects with a suspected WCH state in clinical practice.
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